Adamis Pharmaceuticals Corporation (ADMP) Is Still Worth A Look Despite -72.92% Fall From High – Stocks Register
Home  »  Business   »  Adamis Pharmaceuticals Corporation (ADMP) Is Still...

Adamis Pharmaceuticals Corporation (ADMP) Is Still Worth A Look Despite -72.92% Fall From High

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) concluded the trading at $0.63 on Thursday, January 13 with a fall of -5.06% from its closing price on previous day.

Taking a look at stock we notice that its last check on previous day was $0.67 and 5Y monthly beta was reading 1.23 with its price kept floating in the range of $0.6101 and $0.68 on the day. Considering stock’s 52-week price range provides that ADMP hit a high price of $2.34 and saw its price falling to a low level of $0.55 during that period. Over a period of past 1-month, stock came subtracting -1.52% in its value.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


With its current market valuation of $94.55 million, Adamis Pharmaceuticals Corporation is set to declare its quarterly results on Apr 13, 2022 – Apr 18, 2022. Analysts are in estimates of -$0.04 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to -$0.27 for 2021 with estimates of that growing to -$0.16 in next year. These estimates are suggesting current year growth of 57.80% for EPS and 40.70% growth next year.

Analysts watching the company’s growth closely have provided estimates for its revenue growth with an average revenue estimate of $2.82 million. They suggested that in the process company could generate revenue of as low as $1.3 million which could climb up to $4.34 million to hit a high. The average estimate is representing a decrease of -22.50% in sales growth from that of posted by the company in the same quarter of last year. In keeping analyst consensus estimate with, company is forecasted to be making an annual revenue of $11.61 million in 2021, which will be -29.80% less from revenue generated by the company last year.

In last 7 days, analysts came adjusting their opinions about stock’s EPS with no upward and no downward revisions, an indication which could give clearer idea about the company’s short term price movement. In contrast, when we review ADMP stock’s current outlook then short term indicators are assigning it an average of 50% Sell, while medium term indicators are categorizing the stock at an average of 100% Sell. Long term indicators are suggesting an average of 100% Sell for it.

Digging deeper we become aware of the PEG ratio of the ADMP stock which is currently positioned at 0. It further provides that stock’s current price level is 1.25% away from its 20-day simple moving average and is -17.78% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 45.50 while volatility remained at 15.29% over the past week which changes to 9.29% when measuring it over the past month. Beta is valued at 1.23, while measure of average true range or ATR is currently at 0.06. In predicting price targets of as low as $1.50 and as high as $1.50, analysts are in agreement on assigning the stock over the next 12 months average price target of $1.50. Stock’s current price level is -138.1% above from estimated low price target while it is -138.1% below the estimated high; and even if the ADMP’s share succeeded to reach the median price of $1.50, then the outlook of -138.1% could come to the excitement of the investors.

In comparing Adamis Pharmaceuticals Corporation (ADMP)’s stock with other industry players reveals that stock’s current price change of -5.06% and that of -21.56% over the past 12 months is in competing position with that of SIGA Technologies Inc. (SIGA) which saw its stock price fall by -2.28% in the last trading and went through a decrease of -7.43% in past 12-month trading. Industry’s another major player Johnson & Johnson (JNJ) has fall -0.61% down in previous session, but over the past year has faced a rise of 5.05%, while Pfizer Inc. (PFE) was also down -1.96% however its price remained floating in the green at 51.13% over the same period. Adamis Pharmaceuticals Corporation has a P/E ratio of 0 against that of SIGA Technologies Inc.’s 32.62 while Johnson & Johnson is showing 25.23 for the same. On the other hand, Dow Jones Industrial closed the session lower at -0.49%.

Having a second look at Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) provides that stock’s average daily trading volume for 3 months was 6.45 million. Number of outstanding shares of the stock stood at 148.89 million.

>> 7 Top Picks for the Post-Pandemic Economy <<

The percentage of outstanding shares held by the insiders is 0.50% while it is 10.20% for the institutional holders. Addition of 4.73% by stock’s current price to its year-to-date value in last trading session is likely to be increasing investors’ interest in the stock as it is hinting an extended uptrend.

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Videos

Related Posts



Download Free eBook For


100% free. stop anytime no spam